SCHEMBL6771050

SCHEMBL6771050

CC(C)=Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.73
FBP1 P09467 2/20 0.66
NFE2L2 Q16236 3/20 0.59
VCP P55072 1/20 0.57
CYP19A1 P11511 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
HIF1A Q16665 1/20 0.56
TSHR P16473 3/20 0.55
LMNA P02545 2/20 0.55
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
KDM4E B2RXH2 1/20 0.52
ACHE P22303 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPT P10636 1/20 0.51
MAOB P27338 1/20 0.51
ITGB2 P05107 1/20 0.51
ICAM1 P05362 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611103 0.86 GLO1 (0.69) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL3611099 0.86 GLO1 (0.69) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL3611102 0.86 GLO1 (0.69) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL10507269 0.85 GLO1 (0.68) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL8028846 0.85 GLO1 (1.00) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL10511400 0.85 GLO1 (0.68) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL11441716 0.84 FBP1 (0.78) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL11003223 0.83 GLO1 (0.75) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL2920007 0.83 GLO1 (0.70) GLO1FBP1NFE2L2VCPCYP19A1
SCHEMBL11003226 0.83 GLO1 (0.75) GLO1FBP1NFE2L2VCPCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1951997-A Electric field programmable films and memory device based thereon ROHM & HAAS ELECT MAT (US) 2007-04-25 CN claimed
US-9403854-B2 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2016-08-02 US disclosed
US-9403854-B2 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2016-08-02 US disclosed
US-20140288319-A1 CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-09-25 US disclosed
US-20140288319-A1 CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-09-25 US disclosed
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-07-05 US disclosed
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-07-05 US disclosed
CN-1951997-A Electric field programmable films and memory device based thereon ROHM & HAAS ELECT MAT (US) 2007-04-25 CN disclosed
US-6673824-B1 HYPOTENSIVE AGENTS BRISTOL-MYERS SQUIBB CO. 2004-01-06 US disclosed
US-6107320-A Phenyl sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 2000-08-22 US disclosed
EP-0458207-B1 Indole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1997-03-26 EP disclosed
EP-0569193-B1 N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists SQUIBB & SONS INC (US) 1997-02-26 EP disclosed
US-5514696-A Phenyl sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 1996-05-07 US disclosed
US-5312829-A Testosterone 5alpha-reductase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-05-17 US disclosed
EP-0569193-A1 N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists E.R. SQUIBB & SONS, INC. (US) 1993-11-10 EP disclosed
US-5212320-A Enzyme inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-05-18 US disclosed
EP-0458207-A2 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288319-A1 CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS OXER1, OSTC, OXSR1 GLO1 3850/4885FBP1 1018/4885NFE2L2 110/4885
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts OXER1, OSTC, OXSR1 GLO1 3850/4885FBP1 1018/4885NFE2L2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.